Imagine a tiny, smart cage that can carry both a flashlight to find a tumor and a medicine to destroy it. Instead of using permanent chemical glues, these cages use a magnetic-like attraction to hold everything together, making them easier to build and tune. This allows doctors to see exactly where the cancer is and treat it at the same time, even in hard-to-reach places like the brain.
Traditional radiopharmaceuticals often require separate drugs for diagnosis and therapy, and struggle to penetrate difficult areas like the brain. This leads to fragmented patient care and lower efficacy in treating lung and brain cancers.
A library of supramolecular building blocks, specifically M2L4 metallacages (Pd2+, Pt2+), designed for radiolabeling and bioactive ligand tethering.
If you are a radiopharmaceutical developer dealing with the difficulty of combining diagnostic and therapeutic agents in one molecule — this project developed supramolecular scaffolds that allow for the simultaneous delivery of both. This reduces the need for separate imaging and treatment steps.
If you are a drug delivery specialist dealing with the blood-brain barrier preventing cancer drugs from reaching brain tumors — this project developed non-covalent systems designed for challenging delivery scenarios. This could open new pathways for treating brain and lung cancers.
If you are a precision medicine provider dealing with inaccurate biomarker quantification in cancer patients — this project developed radiotheranostic agents with tailored pharmacokinetics. This allows for more precise characterization of tumor expression.
Based on available project data, there is no information regarding the production cost or market price of the agents.
The project is currently establishing a proof-of-principle and building a library of building blocks; industrial scaling data is not yet available.
Based on available project data, specific patents or licensing terms are not listed, though the project aims to facilitate clinical translation.
The project runs from 2024-01-01 to 2027-12-31, focusing on proof-of-principle and foundational experiments before clinical translation.
It replaces traditional medicinal chemistry approaches with non-covalent systems that combine diagnostic and therapeutic radionuclides in one compound.
The consortium is purely academic and research-driven, consisting of 6 partners from 6 countries. With 4 universities and 2 research organizations, there is a 0% industry ratio, indicating that the current focus is on high-risk fundamental science rather than immediate commercialization.
Contact the Technical University of Munich (TUM) regarding the SMARTdrugs project.
Contact us to monitor this project for upcoming IP filings or spin-off opportunities.
